Retatrutide is still being studied in clinical trials and is not the same as fully approved commercial products
All calculations assume proper laboratory handling, sterile technique, and appropriate storage conditions
Mikki at Medrein Health and Aesthetics in Southlake, TX
The GIP activation appears to buffer gastrointestinal distress rather than compound it, which bodes well for real-world adherence
A key component in reducing the advancement of CKD, RAAS blockers such as angiotensin-converting enzyme inhibitors (ACEIs) do not prevent it from progressing altogether (7)
Last reviewed: June 8, 2026 Last updated: June 8, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations